Increased humoral and cell-mediated immunity has been associated with vaccination against the hepatitis B virus (HBV). HBV stands for the hepatitis B virus. Intralesional HBV vaccination has been utilized in recent attempts at immunotherapy for common warts, with varying degrees of success. The purpose of this research is to evaluate the efficacy and safety of treating multiple common warts with HBV immunization administered intralesionally as opposed to intramuscular (IM).
A total of 60 people with multiple common warts were split into 2 groups for the study: those who received the intralesional HBV vaccine and those who received IM HBV vaccine. Those who received the intralesional HBV vaccine had the vaccine injected into the largest wart at 2-week intervals until clearance, or for a total of 5 sessions. The HBV vaccine was administered intramuscularly thrice, at 0, 1, and 6 months.
About 7 patients in the IM HBV vaccination group (50%) and 15 in the intralesional vaccine group (23.3%) experienced complete wart eradication. The IM group did better than the control group by a statistically significant margin (P=.0479). In both groups, the negative outcomes were relatively minor. The IM version of the HBV vaccine is a safe and effective therapy option for warts.
